🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "major milestone" in the battle against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are on the rise globally, with figures suggesting in excess of 82 million infections annually. Particularly high rates are reported in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the face of rising global incidence, escalating drug resistance and the very limited therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Clearance

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This approval represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

As per results published in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The trial enrolled nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the ability to license and sell the drug in many developing nations.

Doctors treating patients have expressed hope. Access to a one-pill regimen such as this is seen as a "critical tool" for public health efforts. This is considered crucial to reduce the burden of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.